home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Enzyme Double Act Evades Drug Therapy

  January, 25 2007 11:06
your information resource in human molecular genetics
A new Nature study, which sheds light on the varied clinical success of a particular class of cancer drug, known as tyrosine kinase inhibitors, may aid the design of more effective cancer therapies.

Tyrosine kinases are enzymes that modify other proteins by adding phosphate groups to them. Specific tyrosine kinases are overactive in many cancers, and drugs that inhibit them, such as the chronic myeloid leukaemia treatment imatinib, can be successful. But they don't work for all tyrosine-kinase-driven cancers. Researchers think they know why.

One particular kinase, called HER2, is frequently overactive in breast cancers and signals through another family member, HER3. Mark M. Moasser and colleagues now show that when HER2 is inhibited by kinase inhibitors, a feedback mechanism causes an increase of active HER3 at the plasma membrane where it continues to signal cancer cell proliferation (as long as HER2 activity is not completely blocked).

More effective inhibitors are needed to block HER2 completely and reign in HER3. Tests that assess HER3 transphosphorylation could also help to predict any such treatment's success.

Author contact:

Mark M. Moasser (University of California, San Francisco, CA, USA)
E-mail: mmoasser@medicine.ucsf.edu

(C) Nature press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.